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dependence within the uncertainty of the measurements; 
hence no azimuthal and polar correction factors were applied 
to the measurements. No temperature dependence was 
found within the uncertainty of the measurement. The 
measured patient plans were in good agreement with the 
predicted voltage of the dosimeter with the minimum and 
maximum percentage differences between the measured and 
the predicted of -2.6% and -11.3% respectively. Further 
investigation of the causes of these differences and of per 
needle dose measurements to allow real-time error detection 
is still ongoing. Total uncertainty budget of this study was 
9.97% for k=2. An example of a clinical patient result is given 
in the figure.  
 
 
 
Conclusions: Our study has demonstrated that 
implementation of real-time in-vivo dosimetry for HDR 
prostate brachytherapy using a MOSFET is feasible. Gross 
error detection is possible when the MOSFET is placed in a 
low dose gradient and appropriate correction factors are 
applied.  
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Purpose/Objective: To study if real time in vivo dosimetry, 
performed on the rectal surface with MOSkin detectors 
included on the trans rectal ultrasound (TRUS) probe, may 
evaluate possible discrepancies between calculated and 
delivered doses during US-based HDR prostate brachytherapy. 
Materials and Methods: MOSkins are a specific type of 
MOSFET dosimeter, optimized to measure dose in steep dose 
gradients. Their sensitive volume, defined by the volume of 
the gate oxide, is 4.8 x 10-6 mm3. In this study, two MOSkin 
dosimeters were calibrated and assembled on the surface of 
a TRUS-probe, used for real time on-line treatment planning 
in HDR prostate brachytherapy. During the treatment, the 
TRUS-probe was left inside the rectum and real time 
measures of the delivered dose were performed over 14 
treatment sessions (prescribed dose to the target surface: 
14Gy). 
Measured doses were compared to the doses calculated by 
means of the treatment planning system in the estimated 
detector position both on pre-treatment images (i.e., 
acquired 1-2 hours before treatment and used for treatment 
planning) and on post-treatment images (i.e., acquired 
within 3 minutes after treatment). In the latter case, the 
delivered dose distribution was retrospectively reconstructed 
and assumed as the reference. 
Results: Comparison between planned, reconstructed and in 
vivo measured doses, in terms of average absolute 
differences and maximum discrepancies, are given in the 
following table. 
 
 
Data reported in the table shows that the highest accordance 
resulted between MOSkin readings and doses obtained on 
reconstructed plans, suggesting that in particular cases in 
vivo dosimetry might be a better instrument to estimate the 
dose to the rectum rather than the original treatment 
planning system itself. 
Comparing pre- and post-treatment images, it can be 
demonstrated that the high observed discrepancy between 
treatment and reconstructed plans is mainly due to 
anatomical variations of the prostate shape (i.e., prostate 
swelling with expanding inter-needles distances) and position 
(i.e., shift towards the rectal wall). This discrepancy 
correlated with the treatment planning time. 
Conclusions: Doses delivered to the organs at risk during HDR 
prostate brachytherapy might differ significantly from what is 
calculated in the treatment planning phase, providing the 
need for in vivo dosimetry in this particular radiotherapy 
application. MOSkin dosimeters integrated to the TRUS-probe 
proved to be an accurate instrument to perform real time 
measurement of the dose delivered to the rectal wall. The 
use of the dosimeters was incorporated in our department 
into clinical practice, actions protocol are still under study to 
potentially use the information acquired on-line. 
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